Home > News > Advances in Therapeutic Options for Gait and Balance in Parkinson’s Disease
Movement Disorders, Parkinson's Disease
Read Time: 2 mins

Advances in Therapeutic Options for Gait and Balance in Parkinson’s Disease

Published Online: June 27th 2012 European Neurological Review, 2012;7(3):160-8 DOI: http://doi.org/10.17925/ENR.2012.07.03.160
Authors: Nicolaas I Bohnen, Roger L Albin, Martijn LTM Müller, Kelvin L Chou
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

There is a need to explore non-dopaminergic approaches to treating balance and gait problems in Parkinson’s disease (PD). There is emerging evidence on the role of cholinergic denervation of the pedunculopontine nucleus (PPN) thalamus system and falls in PD. Preliminary clinical trial data suggest that the subgroup of PD patients with frequent falls may be suitable candidates for future cholinergic augmentation clinical trials. Recent controlled clinical trials using methylphenidate have been unable to confirm earlier reports of improved gait in PD. Although progressive deterioration of axial motor symptoms occur with deep brain stimulation of the subthalamic nucleus or globus pallidus interna, new preliminary research suggests that other surgical stimulation sites, such as the PPN, may have a potential benefit on gait and balance impairments in PD. Continuing vigorous exercise and physical fitness should be highly encouraged to patients with PD who are at risk of physical deconditioning and fear of falling, but effective antifall physical therapy interventions remain an unmet clinical need.

Keywords

Acetylcholine, dopamine, noradrenergic, deep brain stimulation, exercise, falls, mobility, Parkinson’s disease, pedunculopontine nucleus, striatum, substantia nigra

Article:

Parkinson’s disease (PD) is a clinical syndrome consisting of a variable combination of the four cardinal features of resting tremor, rigidity, bradykinesia and postural instability.1 Akinesia, defined as inability to initiate movement (e.g. gait ignition failure) or sustain movement (e.g. sudden freezes), is considered by some to be the fifth cardinal feature of PD.2 Most motor features of PD are believed to result mainly from loss of striatal dopamine secondary to the degeneration of dopaminergic neurons of the substantia nigra pars compacta (SNpc).3 The greater the neuronal loss in the SNpc, the lower the striatal dopamine concentration and the more severe the parkinsonian symptoms, particularly bradykinesia.4 The rate of disease progression is highly variable among PD patients. Patients with tremor-predominant disease at onset, for example, tend to progress more slowly than patients with early prominent postural instability and gait disturbances (PIGD).5

Clinical characteristics of parkinsonian locomotor patterns include slow gait and reduced angular excursion of joints such as shoulder, knee and trunk joints.6,7 With disease progression, stooped posture, short steps and shuffling (the latter associated with reduced ground clearance and festination) become more prominent features.7–9 Falls are common in PD. Unlike falls in the general population, which result generally from slipping or tripping incidents, the majority of falls in PD occur during routine walking, stopping, turning and standing up or bending down manoeuvres.10,11 One prospective survey of relatively mildly affected PD patients found that 60 % fell during a six-month period and 33 % had multiple falls in this period.12 Fall risk in PD is a bell-shaped function of disease severity,13 reaching a maximum during Hoehn and Yahr stage 3 and decreasing in later stages as patients become less mobile.14,15 The emergence of postural instability marks the onset of increased risk for severe disability in PD patients as up to 40 % of patients with postural instability have multiple falls which may result in injury, including potentially crippling hip and wrist fractures.16

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:
Disclosure

The authors have no conflicts of interest to declare.

Correspondence

Nicolaas I Bohnen, Functional Neuroimaging, Cognitive and Mobility Laboratory, Departments of Radiology and Neurology, University of Michigan, 24 Frank Lloyd Wright Drive, Box 362, Ann Arbor, MI 48105-9755, US. E: nbohnen@umich.edu

Support

The authors gratefully acknowledge research support from the National Institutes of Health (NIH) (National Institute of Neurological Disorders and Stroke [NINDS]), the Department of Veterans Affairs, and the Michael J Fox Foundation.

Received

2011-08-31T00:00:00

References

  1. Quinn N, Parkinsonism-recognition and differential diagnosis, BMJ, 1995;310:447–52.
  2. Factor SA, The clinical spectrum of freezing of gait in atypical parkinsonism, Mov Disord, 2008;23(Suppl. 2):S431–8.
  3. Hughes AJ, Daniel SE, Blankson S, Lees AJ, A clinicopathologic study of 100 cases of Parkinson’s disease, Arch Neurol, 1993;50:140–8.
  4. Bernheimer H, Birkmayer W, Hornykiewicz O, et al., Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations, J Neurol Sci, 1973;20:415–55.
  5. Post B, Merkus MP, de Haan RJ, Speelman JD, Prognostic factors for the progression of Parkinson’s disease: a systematic review, Mov Disord, 2007;22:1839–51; quiz 1988.
  6. Azulay JP, Van Den Brand C, Mestre D, et al., [Automatic motion analysis of gait in patients with Parkinson disease: effects of levodopa and visual stimulations], Rev Neurol (Paris), 1996;152:128–34. Article in French.
  7. Kemoun G, Defebvre L, [Clinical description, analysis of posture, initiation of stabilized gait], Presse Med, 2001;30:452–9. Article in French.
  8. Murray MP, Sepic SB, Gardner GM, Downs WJ, Walking patterns of men with parkinsonism, Am J Phys Med, 1978;57:278–94.
  9. Nieuwboer A, Dom R, De Weerdt W, et al., Abnormalities of the spatiotemporal characteristics of gait at the onset of freezing in Parkinson’s disease, Mov Disord, 2001;16:1066–75.
  10. Bloem BR, Grimbergen YA, Cramer M, et al., Prospective assessment of falls in Parkinson’s disease, J Neurol, 2001;248:950–8.
  11. Morris ME, Movement disorders in people with Parkinson disease: a model for physical therapy, Phys Ther, 2000;80:578–97.
  12. Bloem BR, Grimbergen YAM, Cramer M, et al., Prospective assessment of falls in Parkinson’s disease, Mov Disord, 1998;10:147.
  13. Pickering RM, Mazibrada G, Wood BH, et al., A meta-analysis of six prospective studies of falls in Parkinson’s disease, Mov Disord, 2004;19:S262.
  14. Bloem BR, van Vugt JP, Beckley DJ, Postural instability and falls in Parkinson’s disease, Adv Neurol, 2001;87:209–23.
  15. Wood BH, Bilclough JA, Bowron A, Walker RW, Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study, J Neurol Neurosurg Psychiatry, 2002;72:721–5.
  16. Gray P, Hildebrand K, Fall risk factors in Parkinson’s disease, J Neurosci Nurs, 2000;32:222–8.
  17. Bohnen NI, Cham R, Postural control, gait, and dopamine functions in parkinsonian movement disorders, Clin Geriatr Med, 2006;22:797–812.
  18. Bowes SG, Clark PK, Leeman AL, et al., Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy, Br J Clin Pharmacology, 1990;30:13–24.
  19. Ferrandez AM, Blin O, A comparison between the effect of intentional modulations and the action of L-dopa on gait in Parkinson’s disease, Behav Brain Res, 1991;45:177–83.
  20. O’Sullivan JD, Said CM, Dillon LC, et al., Gait analysis in patients with Parkinson’s disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function, Mov Disord, 1998;13:900–6.
  21. Shan DE, Lee SJ, Chao LY, Yeh SI, Gait analysis in advanced Parkinson’s disease—effect of levodopa and tolcapone, Can J Neurol Sci, 2001;28:70–5.
  22. Blin O, Ferrandez AM, Pailhous J, Serratrice G, Dopa-sensitive and dopa-resistant gait parameters in Parkinson’s disease, J Neurol Sci, 1991;103:51–4.
  23. Ebersbach G, Heijmenberg M, Kindermann L, et al., Interference of rhythmic constraint on gait in healthy subjects and patients with early Parkinson’s disease: evidence for impaired locomotor pattern generation in early Parkinson’s disease., Mov Disord, 1999;14:619–25.
  24. Rossignol S, Dubuc R, Gossard JP, Dynamic sensorimotor interactions in locomotion, Physiol Rev, 2006;86:89–154.
  25. Mori S, Matsui T, Kuze B, et al., Stimulation of a restricted region in the midline cerebellar white matter evokes coordinated quadrupedal locomotion in the decerebrate cat, J Neurophysiol, 1999;82:290–300.
  26. Shik ML, Orlovsky GN, Neurophysiology of locomotor automatism, Physiol Rev, 1976;56:465–501.
  27. Alexander GE, DeLong MR, Strick PL, Parallel organization of functionally segregated circuits linking basal ganglia and cortex, Annu Rev Neurosci, 1986;9:357–81.
  28. Redgrave P, Rodriguez M, Smith Y, et al., Goal-directed and habitual control in the basal ganglia: implications for Parkinson’s disease, Nat Rev Neurosci, 2010;11:760–72.
  29. Balleine BW, O’Doherty JP, Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action, Neuropsychopharmacology, 2010;35:48–69.
  30. Yin HH, Knowlton BJ, The role of the basal ganglia in habit formation, Nat Rev Neurosci, 2006;7:464–76.
  31. Latt LD, Sparto PJ, Furman JM, Redfern MS, The steady-state postural response to continuous sinusoidal galvanic vestibular stimulation, Gait Posture, 2003;18:64–72.
  32. Horak FB, Shupert CL, Dietz V, Horstmann G, Vestibular and somatosensory contributions to responses to head and body displacements in stance, Exp Brain Res, 1994;100:93–106.
  33. Mahboobin A, Loughlin PJ, Redfern MS, Sparto PJ, Sensory re-weighting in human postural control during moving-scene perturbations, Exp Brain Res, 2005;167:260–7.
  34. Visser JE, Bloem BR, Role of the basal ganglia in balance control, Neural Plast, 2005;12:161–74.
  35. Burleigh-Jacobs A, Horak FB, Nutt JG, Obeso JA, Step initiation in Parkinson’s disease: influence of levodopa and external sensory triggers, Mov Disord, 1997;12:206–15.
  36. Giladi N, Treves TA, Simon ES, et al., Freezing of gait in patients with advanced Parkinson’s disease, J Neural Transm, 2001;108:53–61.
  37. Snijders AH, Toni I, Ruzicka E, Bloem BR, Bicycling breaks the ice for freezers of gait, Mov Disord, 2011;26:367–71.
  38. Kish SJ, Shannak K, Hornykiewicz O, Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease, N Engl J Med, 1988;318:876–80.
  39. Ouchi Y, Kanno T, Okada H, et al., Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson’s disease, Brain, 2001;124:784–92.
  40. Bartels AL, de Jong BM, Giladi N, et al., Striatal dopa and glucose metabolism in PD patients with freezing of gait, Mov Disord, 2006;21:1326–32.
  41. Azulay JP, Mesure S, Amblard B, et al., Visual control of locomotion in Parkinson’s disease, Brain, 1999;122:111–20.
  42. Lewis GN, Byblow WD, Walt SE, Stride length regulation in Parkinson’s disease: the use of extrinsic, visual cues, Brain, 2000;123:2077–90.
  43. McIntosh GC, Brown SH, Rice RR, Thaut MH, Rhythmic auditory-motor facilitation of gait patterns in patients with Parkinson’s disease, J Neurol Neurosurg Psychiatry, 1997;62:22–6.
  44. Thaut MH, McIntosh GC, Rice RR, et al., Rhythmic auditory stimulation in gait training for Parkinson’s disease patients, Mov Dis, 1996;11:193–200.
  45. Howe TE, Lovgreen B, Cody FW, et al., Auditory cues can modify the gait of persons with early-stage Parkinson’s disease: a method for enhancing parkinsonian walking performance?, Clin Rehabilitation, 2003;17:363–7.
  46. Woollacott M, Shumway-Cook A, Attention and the control of posture and gait: a review of an emerging area of research, Gait Posture, 2002;16:1–14.
  47. Lundin-Olsson L, Nyberg L, Gustafson Y, ‘Stops walking when talking’ as a predictor of falls in elderly people, Lancet, 1997;349:617.
  48. Lees AJ, Smith E, Cognitive deficits in the early stages of Parkinson’s disease, Brain, 1983;106:257–70.
  49. Dubois B, Pillon B, Cognitive deficits in Parkinson’s disease, J Neurology, 1997;244:2–8.
  50. Stuss DT, Alexander MP, Executive functions and the frontal lobes: a conceptual view, Psychological Res, 2000;63:289–98.
  51. Bloem BR, Valkenburg VV, Slabbekoorn M, van Dijk JG, The multiple tasks test. Strategies in Parkinson’s disease, Exp Brain Res, 2001;137:478–86.
  52. Yogev G, Giladi N, Peretz C, et al., Dual tasking, gait rhythmicity, and Parkinson’s disease: which aspects of gait are attention demanding?, Eur J Neurosci, 2005;22:1248–56.
  53. Marchese R, Bove M, Abbruzzese G, Effect of cognitive and motor tasks on postural stability in Parkinson’s disease: a posturographic study, Mov Disord, 2003;18:652–8.
  54. Camicioli R, Oken BS, Sexton G, et al., Verbal fluency task affects gait in Parkinson’s disease with motor freezing, J Geriatr Psychiatry Neurology, 1998;11:181–5.
  55. Bond JM, Morris M, Goal-directed secondary motor tasks: their effects on gait in subjects with Parkinson disease, Arch Phys Med Rehabilitation, 2000;81:110–6.
  56. O’Shea S, Morris ME, Iansek R, Dual task interference during gait in people with Parkinson disease: effects of motor versus cognitive secondary tasks, Phys Ther, 2002;82:888–97.
  57. Hausdorff JM, Schaafsma JD, Balash Y, et al., Impaired regulation of stride variability in Parkinson’s disease subjects with freezing of gait, Exp Brain Res, 2003;149:187–94.
  58. Hausdorff JM, Cudkowicz ME, Firtion R, et al., Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson’s disease and Huntington’s disease, Mov Disord, 1998;13:428–37.
  59. Springer S, Giladi N, Peretz C, et al., Dual-tasking effects on gait variability: the role of aging, falls, and executive function, Mov Disord, 2006;21:950–7.
  60. Hausdorff JM, Balash J, Giladi N, Effects of cognitive challenge on gait variability in patients with Parkinson’s disease, J Geriatr Psychiatry Neurology, 2003;16:53–8.
  61. Jellinger K, The pedunculopontine nucleus in Parkinson’s disease, progressive supranuclear palsy and Alzheimer’s disease, J Neurol Neurosurg Psychiatry, 1988;51:540–3.
  62. Braak H, Del Tredici K, Nervous system pathology in sporadic Parkinson disease, Neurology, 2008;70:1916–25.
  63. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F, Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy, Proc Natl Acad Sci U S A, 1987;84:5976–80.
  64. Lee MS, Rinne JO, Marsden CD, The pedunculopontine nucleus: its role in the genesis of movement disorders, Yonsei Med J, 2000;41:167–84.
  65. Stein JF, Akinesia, motor oscillations and the pedunculopontine nucleus in rats and men, Exp Neurol, 2009;215:1–4.
  66. Pahapill PA, Lozano AM, The pedunculopontine nucleus and Parkinson’s disease, Brain, 2000;123:1767–83.
  67. Alam M, Schwabe K, Krauss JK, The pedunculopontine nucleus area: critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation, Brain, 2011;134:11–23.
  68. Heckers S, Geula C, Mesulam M, Cholinergic innervation of the human thalamus: Dual origin and differential nuclear distribution, J Comp Neurol, 1992;325:68–82.
  69. Winn P, How best to consider the structure and function of the pedunculopontine tegmental nucleus: evidence from animal studies, J Neurol Sci, 2006;248:234–50.
  70. Lavoie B, Parent A, Pedunculopontine nucleus in the squirrel monkey: projections to the basal ganglia as revealed by anterograde tract-tracing methods, J Comp Neurol, 1994;344:210–31.
  71. Zweig RM, Jankel WR, Hedreen JC, et al., The pedunculopontine nucleus in Parkinson’s disease, Ann Neurol, 1989;26:41–6.
  72. Gai WP, Halliday GM, Blumbergs PC, et al., Substance Pcontaining neurons in the mesopontine tegmentum are severely affected in Parkinson’s disease, Brain, 1991;114:2253–67.
  73. Karachi C, Grabli D, Bernard FA, et al., Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease, J Clin Invest, 2010;120:2745–54.
  74. Jenkinson N, Nandi D, Miall RC, et al., Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey, Neuroreport, 2004;15:2621–4.
  75. Garcia-Rill E, Houser CR, Skinner RD, et al., Locomotioninducing sites in the vicinity of the pedunculopontine nucleus, Brain Res Bull, 1987;18:731–8.
  76. Hasselmo ME, Sarter M, Modes and models of forebrain cholinergic neuromodulation of cognition, Neuropsychopharmacology, 2011;36:52–73.
  77. Bohnen NI, Kaufer DI, Ivanco LS, et al., Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study, Arch Neurol, 2003;60:1745–8.
  78. Shimada H, Hirano S, Shinotoh H, et al., Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET, Neurology, 2009;73:273–8.
  79. Bohnen NI, Albin RL, The cholinergic system and Parkinson disease, Behav Brain Res, 2011;221:564–73.
  80. Spuz CA, Paolone G, Briscoe S, et al., Deficits in attentional control of balance, mobility, and complex movements in a rat model of early state, multisystem Parkinson disease, Society for Neuroscience, Washington DC, November 2011, Abstract 244.02.
  81. Bohnen NI, Muller ML, Koeppe RA, et al., History of falls in Parkinson disease is associated with reduced cholinergic activity, Neurology, 2009;73:1670–6.
  82. Alves G, Larsen JP, Emre M, et al., Changes in motor subtype and risk for incident dementia in Parkinson’s disease, Mov Disord, 2006;21:1123–30.
  83. Taylor JP, Rowan EN, Lett D, et al., Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype, J Neurol Neurosurg Psychiatry, 2008;79:1318–23.
  84. Grimbergen YA, Langston JW, Roos RA, Bloem BR, Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus, Expert Rev Neurother, 2009;9:279–90.
  85. Moore RY, Bloom FE, Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems, Annu Rev Neurosci, 1979;2:113–68.
  86. Zarow C, Lyness SA, Mortimer JA, Chui HC, Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases, Arch Neurol, 2003;60:337–41.
  87. Gunning-Dixon FM, Raz N, The cognitive correlates of white matter abnormalities in normal aging: A quantitative review, Neuropsychology, 2000;14:224–32.
  88. Pantoni L, Garcia JH, Pathogenesis of leukoaraiosis, Stroke, 1997;28:652–9.
  89. Longstreth WT, Jr, Manolio TA, Arnold A, et al., Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study, Stroke, 1996;27:1274–82.
  90. Baezner H, Blahak C, Poggesi A, et al., Association of gait and balance disorders with age-related white matter changes: the LADIS study, Neurology, 2008;70:935–42.
  91. Murray ME, Senjem ML, Petersen RC, et al., Functional impact of white matter hyperintensities in cognitively normal elderly subjects, Arch Neurol, 2010;67:1379–85.
  92. Bohnen NI, Muller ML, Zarzhevsky N, et al., Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson’s disease, Brain, 2011;134:2358–65.
  93. Schneider JA, Bennett DA, Where vascular meets neurodegenerative disease, Stroke, 2010;41:S144–6.
  94. Chung KA, Lobb BM, Nutt JG, Horak F, Cholinergic augmentation in frequently fallings subjects with Parkinson’s disease, Mov Disord, 2009;24(Suppl. 1):S259.
  95. Ceravolo R, Volterrani D, Frosini D, et al., Brain perfusion effects of cholinesterase inhibitors in Parkinson’s disease with dementia, J Neural Transm, 2006;113:1787–90.
  96. Ahlskog JE, Think before you leap: donepezil reduces falls?, Neurology, 2010;75:1226–7.
  97. Montero-Odasso M, Wells J, Borrie M, Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls, J Am Geriatr Soc, 2009;57:359–60.
  98. Sarter M, Parikh V, Howe WM, nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms, Biochem Pharmacol, 2009;78:658–67.
  99. Pollak L, Dobronevsky Y, Prohorov T, et al., Low dose methylphenidate improves freezing in advanced Parkinson’s disease during off-state, J Neural Transm Suppl, 2007:145–8.
  100. Devos D, Krystkowiak P, Clement F, et al., Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease, J Neurol Neurosurg Psychiatry, 2007;78:470–5.
  101. Auriel E, Hausdorff JM, Herman T, et al., Effects of methylphenidate on cognitive function and gait in patients with Parkinson’s disease: a pilot study, Clin Neuropharmacol, 2006;29:15–7.
  102. Nutt JG, Carter JH, Carlson NE, Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial, Arch Neurol, 2007;64:319–23.
  103. Auriel E, Hausdorff JM, Giladi N, Methylphenidate for the treatment of Parkinson disease and other neurological disorders, Clin Neuropharmacol, 2009;32:75–81.
  104. Espay AJ, Dwivedi AK, Payne M, et al., Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial, Neurology, 2011;76:1256–62.
  105. Jankovic J, Atomoxetine for freezing of gait in Parkinson disease, J Neurol Sci, 2009;284:177–8.
  106. Benabid AL, Pollak P, Gervason C, et al., Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus, Lancet, 1991;337:403–6.
  107. Deuschl G, Bain P, Deep brain stimulation for tremor [correction of trauma]: patient selection and evaluation, Mov Disord, 2002;17(Suppl. 3):S102–11.
  108. Pahwa R, Lyons KE, Wilkinson SB, et al., Long-term evaluation of deep brain stimulation of the thalamus, J Neurosurg, 2006;104:506–12.
  109. Bakker M, Esselink RA, Munneke M, et al., Effects of stereotactic neurosurgery on postural instability and gait in Parkinson’s disease, Mov Disord, 2004;19:1092–9.
  110. Weaver FM, Follett K, Stern M, et al., Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial, JAMA, 2009;301:63–73.
  111. Follett KA, Weaver FM, Stern M, et al., Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease, N Engl J Med, 2010;362:2077–91.
  112. Krack P, Batir A, Van Blercom N, et al., Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease, N Engl J Med, 2003;349:1925–34.
  113. Liang GS, Chou KL, Baltuch GH, et al., Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson’s disease, Stereotact Funct Neurosurg, 2006;84:221–7.
  114. Ostergaard K, Aa Sunde N, Evolution of Parkinson’s disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus, Mov Disord, 2006;21:624–31.
  115. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al., Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up, Brain, 2005;128:2240–9.
  116. Schupbach WM, Chastan N, Welter ML, et al., Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up, J Neurol Neurosurg Psychiatry, 2005;76:1640–4.
  117. Castrioto A, Lozano AM, Poon YY, et al., Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation, Arch Neurol, 2011;68:1550–6.
  118. St George RJ, Nutt JG, Burchiel KJ, Horak FB, A metaregression of the long-term effects of deep brain stimulation on balance and gait in PD, Neurology, 2010;75:1292–9.
  119. Moreau C, Defebvre L, Destee A, et al., STN-DBS frequency effects on freezing of gait in advanced Parkinson disease, Neurology, 2008;71:80–4.
  120. Brozova H, Barnaure I, Alterman RL, Tagliati M, STN-DBS frequency effects on freezing of gait in advanced Parkinson disease, Neurology, 2009;72:770; author reply 770–1.
  121. Brudzynski SM, Houghton PE, Brownlee RD, Mogenson GJ, Involvement of neuronal cell bodies of the mesencephalic locomotor region in the initiation of locomotor activity of freely behaving rats, Brain Res Bull, 1986;16:377–81.
  122. Milner KL, Mogenson GJ, Electrical and chemical activation of the mesencephalic and subthalamic locomotor regions in freely moving rats, Brain Res, 1988;452:273–85.
  123. Plaha P, Gill SS, Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s disease, Neuroreport, 2005;16:1883–7.
  124. Bacskai BJ, Frosch MP, Freeman SH, et al., Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report, Arch Neurol, 2007;64:431–4.
  125. Ferraye MU, Debu B, Fraix V, et al., Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s disease, Brain, 2010;133:205–14.
  126. Moro E, Hamani C, Poon YY, et al., Unilateral pedunculopontine stimulation improves falls in Parkinson’s disease, Brain, 2010;133:215–24.
  127. Ostrem JL, Christine CW, Glass GA, et al., Pedunculopontine nucleus deep brain stimulation in a patient with primary progressive freezing gait disorder, Stereotact Funct Neurosurg, 2010;88:51–5.
  128. Zrinzo L, Zrinzo LV, Surgical anatomy of the pedunculopontine and peripeduncular nuclei, Br J Neurosurg, 2008;22(Suppl. 1):S19–24.
  129. Khan S, Mooney L, Plaha P, et al., Outcomes from stimulation of the caudal zona incerta and pedunculopontine nucleus in patients with Parkinson’s disease, Br J Neurosurg, 2011;25:273–80.
  130. Morris ME, Martin CL, Schenkman ML, Striding out with Parkinson disease: evidence-based physical therapy for gait disorders, Phys Ther, 2010;90:280–8.
  131. Kwakkel G, de Goede CJ, van Wegen EE, Impact of physical therapy for Parkinson’s disease: a critical review of the literature, Parkinsonism Relat Disord, 2007;13(Suppl. 3):S478–87.
  132. Goodwin VA, Richards SH, Taylor RS, et al., The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis, Mov Disord, 2008;23:631–40.
  133. Dibble LE, Addison O, Papa E, The effects of exercise on balance in persons with Parkinson’s disease: a systematic review across the disability spectrum, J Neurol Phys Ther, 2009;33:14–26.
  134. Allen NE, Sherrington C, Paul SS, Canning CG, Balance and falls in Parkinson’s disease: A meta-analysis of the effect of exercise and motor training, Mov Disord, 2011;26:1605–15.
  135. Cakit BD, Saracoglu M, Genc H, et al., The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson’s disease, Clin Rehabil, 2007;21:698–705.
  136. Mehrholz J, Friis R, Kugler J, et al., Treadmill training for patients with Parkinson’s disease, Cochrane Database Syst Rev, 2010;(1):CD007830.
  137. Hackney ME, Earhart GM, Tai Chi improves balance and mobility in people with Parkinson disease, Gait Posture, 2008;28:456–60.
  138. Ridgel AL, Kim CH, Fickes EJ, et al., Changes in executive function after acute bouts of passive cycling in Parkinson’s disease, J Aging Phys Act, 2011;19:87–98.

Further Resources

Share this Article
Related Content In Parkinson's Disease
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72